{
  "slate_id": "469bb270-a423-4929-96bd-6eaadeb7986b",
  "generated_from": {
    "registry_path": "slates/2026-Q1/registry.parquet",
    "outcomes_path": "slates/2026-Q1/outcomes.parquet"
  },
  "diseases": [
    {
      "key": "amyotrophic lateral sclerosis",
      "label": "amyotrophic lateral sclerosis",
      "prediction_count": 50,
      "outcome_count": 2
    },
    {
      "key": "glioblastoma",
      "label": "Glioblastoma",
      "prediction_count": 50,
      "outcome_count": 80
    },
    {
      "key": "idiopathic pulmonary fibrosis",
      "label": "Idiopathic pulmonary fibrosis",
      "prediction_count": 50,
      "outcome_count": 0
    },
    {
      "key": "systemic lupus erythematosus",
      "label": "Systemic lupus erythematosus",
      "prediction_count": 50,
      "outcome_count": 2
    },
    {
      "key": "triple negative breast cancer",
      "label": "triple negative breast cancer",
      "prediction_count": 50,
      "outcome_count": 10
    },
    {
      "key": "type 2 diabetes",
      "label": "type 2 diabetes",
      "prediction_count": 50,
      "outcome_count": 6
    },
    {
      "key": "ulcerative colitis",
      "label": "Ulcerative colitis",
      "prediction_count": 50,
      "outcome_count": 2
    }
  ],
  "predictions_by_disease": {
    "glioblastoma": [
      {
        "drug_name": "AMMONIUM LACTATE",
        "score": 0.9909,
        "rank": 1,
        "tier": "high",
        "falsification": "AMMONIUM LACTATE enters Phase 2+ trial for Glioblastoma within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "LEFLUNOMIDE",
        "score": 0.9888,
        "rank": 2,
        "tier": "high",
        "falsification": "LEFLUNOMIDE enters Phase 2+ trial for Glioblastoma within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "zanubrutinib",
        "score": 0.9888,
        "rank": 3,
        "tier": "high",
        "falsification": "zanubrutinib enters Phase 2+ trial for Glioblastoma within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "DOCETAXEL",
        "score": 0.9862,
        "rank": 4,
        "tier": "high",
        "falsification": "DOCETAXEL enters Phase 2+ trial for Glioblastoma within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "PEMETREXED DISODIUM",
        "score": 0.9854,
        "rank": 5,
        "tier": "high",
        "falsification": "PEMETREXED DISODIUM enters Phase 2+ trial for Glioblastoma within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "DUVELISIB",
        "score": 0.9828,
        "rank": 6,
        "tier": "high",
        "falsification": "DUVELISIB enters Phase 2+ trial for Glioblastoma within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "LEUCOVORIN CALCIUM",
        "score": 0.9807,
        "rank": 7,
        "tier": "high",
        "falsification": "LEUCOVORIN CALCIUM enters Phase 2+ trial for Glioblastoma within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "CP-724714",
        "score": 0.9793,
        "rank": 8,
        "tier": "high",
        "falsification": "CP-724714 enters Phase 2+ trial for Glioblastoma within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "EPIRUBICIN",
        "score": 0.9756,
        "rank": 9,
        "tier": "high",
        "falsification": "EPIRUBICIN enters Phase 2+ trial for Glioblastoma within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "IMATINIB",
        "score": 0.9749,
        "rank": 10,
        "tier": "high",
        "falsification": "IMATINIB enters Phase 2+ trial for Glioblastoma within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "DOXORUBICIN HYDROCHLORIDE",
        "score": 0.9729,
        "rank": 11,
        "tier": "moderate",
        "falsification": "DOXORUBICIN HYDROCHLORIDE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "score": 0.9709,
        "rank": 12,
        "tier": "moderate",
        "falsification": "SORAFENIB TOSYLATE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "Alpelisib",
        "score": 0.9685,
        "rank": 13,
        "tier": "moderate",
        "falsification": "Alpelisib enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "SELUMETINIB",
        "score": 0.9648,
        "rank": 14,
        "tier": "moderate",
        "falsification": "SELUMETINIB enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "Colchicine",
        "score": 0.9643,
        "rank": 15,
        "tier": "moderate",
        "falsification": "Colchicine enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "Digoxin",
        "score": 0.9635,
        "rank": 16,
        "tier": "moderate",
        "falsification": "Digoxin enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "TAMOXIFEN CITRATE",
        "score": 0.9629,
        "rank": 17,
        "tier": "moderate",
        "falsification": "TAMOXIFEN CITRATE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "DOVITINIB",
        "score": 0.9605,
        "rank": 18,
        "tier": "moderate",
        "falsification": "DOVITINIB enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "score": 0.9595,
        "rank": 19,
        "tier": "moderate",
        "falsification": "IRINOTECAN HYDROCHLORIDE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "PEMETREXED MONOHYDRATE",
        "score": 0.9554,
        "rank": 20,
        "tier": "moderate",
        "falsification": "PEMETREXED MONOHYDRATE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "TESETAXEL",
        "score": 0.9546,
        "rank": 21,
        "tier": "moderate",
        "falsification": "TESETAXEL enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "RAMUCIRUMAB",
        "score": 0.9526,
        "rank": 22,
        "tier": "moderate",
        "falsification": "RAMUCIRUMAB enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "tepotinib",
        "score": 0.9525,
        "rank": 23,
        "tier": "moderate",
        "falsification": "tepotinib enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "entrectinib",
        "score": 0.952,
        "rank": 24,
        "tier": "moderate",
        "falsification": "entrectinib enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "RIBAVIRIN",
        "score": 0.9514,
        "rank": 25,
        "tier": "moderate",
        "falsification": "RIBAVIRIN enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "midostaurin",
        "score": 0.9488,
        "rank": 26,
        "tier": "moderate",
        "falsification": "midostaurin enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "tucatinib",
        "score": 0.9451,
        "rank": 27,
        "tier": "moderate",
        "falsification": "tucatinib enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "TEPOTINIB HYDROCHLORIDE",
        "score": 0.9396,
        "rank": 28,
        "tier": "moderate",
        "falsification": "TEPOTINIB HYDROCHLORIDE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "BUSULFAN",
        "score": 0.9367,
        "rank": 29,
        "tier": "moderate",
        "falsification": "BUSULFAN enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "EPIRUBICIN HYDROCHLORIDE",
        "score": 0.9277,
        "rank": 30,
        "tier": "moderate",
        "falsification": "EPIRUBICIN HYDROCHLORIDE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "ABT 737",
        "score": 0.9254,
        "rank": 31,
        "tier": "moderate",
        "falsification": "ABT 737 enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "HEXACHLOROPHENE",
        "score": 0.9228,
        "rank": 32,
        "tier": "moderate",
        "falsification": "HEXACHLOROPHENE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "OSI-632",
        "score": 0.9227,
        "rank": 33,
        "tier": "moderate",
        "falsification": "OSI-632 enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "TOVORAFENIB",
        "score": 0.9197,
        "rank": 34,
        "tier": "moderate",
        "falsification": "TOVORAFENIB enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "score": 0.9168,
        "rank": 35,
        "tier": "moderate",
        "falsification": "SUNITINIB MALATE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "PEMETREXED TROMETHAMINE",
        "score": 0.9158,
        "rank": 36,
        "tier": "moderate",
        "falsification": "PEMETREXED TROMETHAMINE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "PINDOLOL",
        "score": 0.9147,
        "rank": 37,
        "tier": "moderate",
        "falsification": "PINDOLOL enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "MECHLORETHAMINE HYDROCHLORIDE",
        "score": 0.9141,
        "rank": 38,
        "tier": "moderate",
        "falsification": "MECHLORETHAMINE HYDROCHLORIDE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "MITOXANTRONE HYDROCHLORIDE",
        "score": 0.9135,
        "rank": 39,
        "tier": "moderate",
        "falsification": "MITOXANTRONE HYDROCHLORIDE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "PIRTOBRUTINIB",
        "score": 0.908,
        "rank": 40,
        "tier": "moderate",
        "falsification": "PIRTOBRUTINIB enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "Thioguanine",
        "score": 0.8994,
        "rank": 41,
        "tier": "moderate",
        "falsification": "Thioguanine enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "Azathioprine",
        "score": 0.8948,
        "rank": 42,
        "tier": "moderate",
        "falsification": "Azathioprine enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "DACARBAZINE",
        "score": 0.8891,
        "rank": 43,
        "tier": "moderate",
        "falsification": "DACARBAZINE enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "Prochlorperazine",
        "score": 0.889,
        "rank": 44,
        "tier": "moderate",
        "falsification": "Prochlorperazine enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "DACTINOMYCIN",
        "score": 0.8862,
        "rank": 45,
        "tier": "moderate",
        "falsification": "DACTINOMYCIN enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "score": 0.8839,
        "rank": 46,
        "tier": "moderate",
        "falsification": "SUNITINIB MALATE enters Phase 1+ trial for glioblastoma within 5 years"
      },
      {
        "drug_name": "LEVOLEUCOVORIN",
        "score": 0.8802,
        "rank": 47,
        "tier": "moderate",
        "falsification": "LEVOLEUCOVORIN enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "DOCETAXEL ANHYDROUS",
        "score": 0.8725,
        "rank": 48,
        "tier": "moderate",
        "falsification": "DOCETAXEL ANHYDROUS enters Phase 1+ trial for Glioblastoma within 5 years"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "score": 0.8706,
        "rank": 49,
        "tier": "moderate",
        "falsification": "SORAFENIB TOSYLATE enters Phase 1+ trial for glioblastoma within 5 years"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "score": 0.8696,
        "rank": 50,
        "tier": "moderate",
        "falsification": "IRINOTECAN HYDROCHLORIDE enters Phase 1+ trial for glioblastoma within 5 years"
      }
    ],
    "idiopathic pulmonary fibrosis": [
      {
        "drug_name": "BUDESONIDE",
        "score": 0.9385,
        "rank": 1,
        "tier": "high",
        "falsification": "BUDESONIDE enters Phase 2+ trial for Idiopathic pulmonary fibrosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "PILOCARPINE HYDROCHLORIDE",
        "score": 0.93,
        "rank": 2,
        "tier": "high",
        "falsification": "PILOCARPINE HYDROCHLORIDE enters Phase 2+ trial for Idiopathic pulmonary fibrosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "OXALIPLATIN",
        "score": 0.9195,
        "rank": 3,
        "tier": "high",
        "falsification": "OXALIPLATIN enters Phase 2+ trial for Idiopathic pulmonary fibrosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "IFOSFAMIDE",
        "score": 0.9124,
        "rank": 4,
        "tier": "high",
        "falsification": "IFOSFAMIDE enters Phase 2+ trial for Idiopathic pulmonary fibrosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "CISPLATIN",
        "score": 0.9084,
        "rank": 5,
        "tier": "high",
        "falsification": "CISPLATIN enters Phase 2+ trial for Idiopathic pulmonary fibrosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "TEMOZOLOMIDE",
        "score": 0.9027,
        "rank": 6,
        "tier": "high",
        "falsification": "TEMOZOLOMIDE enters Phase 2+ trial for Idiopathic pulmonary fibrosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "LEUCOVORIN",
        "score": 0.8985,
        "rank": 7,
        "tier": "high",
        "falsification": "LEUCOVORIN enters Phase 2+ trial for Idiopathic pulmonary fibrosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Colchicine",
        "score": 0.8939,
        "rank": 8,
        "tier": "high",
        "falsification": "Colchicine enters Phase 2+ trial for Idiopathic pulmonary fibrosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "MAGNESIUM SULFATE",
        "score": 0.8854,
        "rank": 9,
        "tier": "high",
        "falsification": "MAGNESIUM SULFATE enters Phase 2+ trial for Idiopathic pulmonary fibrosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "brexpiprazole",
        "score": 0.882,
        "rank": 10,
        "tier": "high",
        "falsification": "brexpiprazole enters Phase 2+ trial for idiopathic pulmonary fibrosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "DACARBAZINE",
        "score": 0.8607,
        "rank": 11,
        "tier": "moderate",
        "falsification": "DACARBAZINE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "ERLOTINIB HYDROCHLORIDE",
        "score": 0.852,
        "rank": 12,
        "tier": "moderate",
        "falsification": "ERLOTINIB HYDROCHLORIDE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "BUSULFAN",
        "score": 0.8479,
        "rank": 13,
        "tier": "moderate",
        "falsification": "BUSULFAN enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "DEFLAZACORT",
        "score": 0.832,
        "rank": 14,
        "tier": "moderate",
        "falsification": "DEFLAZACORT enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "deucravacitinib",
        "score": 0.83,
        "rank": 15,
        "tier": "moderate",
        "falsification": "deucravacitinib enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "HYDROCORTISONE SODIUM SUCCINATE",
        "score": 0.8277,
        "rank": 16,
        "tier": "moderate",
        "falsification": "HYDROCORTISONE SODIUM SUCCINATE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "CLARITHROMYCIN",
        "score": 0.8142,
        "rank": 17,
        "tier": "moderate",
        "falsification": "CLARITHROMYCIN enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "Hydrocortisone",
        "score": 0.8137,
        "rank": 18,
        "tier": "moderate",
        "falsification": "Hydrocortisone enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "P",
        "score": 0.8097,
        "rank": 19,
        "tier": "moderate",
        "falsification": "P enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "tocilizumab",
        "score": 0.8094,
        "rank": 20,
        "tier": "moderate",
        "falsification": "tocilizumab enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "FOLIC ACID",
        "score": 0.8023,
        "rank": 21,
        "tier": "moderate",
        "falsification": "FOLIC ACID enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "VORICONAZOLE",
        "score": 0.8019,
        "rank": 22,
        "tier": "moderate",
        "falsification": "VORICONAZOLE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "RAMUCIRUMAB",
        "score": 0.8005,
        "rank": 23,
        "tier": "moderate",
        "falsification": "RAMUCIRUMAB enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "DULOXETINE",
        "score": 0.7998,
        "rank": 24,
        "tier": "moderate",
        "falsification": "DULOXETINE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "Gefitinib",
        "score": 0.7833,
        "rank": 25,
        "tier": "moderate",
        "falsification": "Gefitinib enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "PERIFOSINE",
        "score": 0.768,
        "rank": 26,
        "tier": "moderate",
        "falsification": "PERIFOSINE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "Loteprednol Etabonate",
        "score": 0.7597,
        "rank": 27,
        "tier": "moderate",
        "falsification": "Loteprednol Etabonate enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "FLUCONAZOLE",
        "score": 0.7591,
        "rank": 28,
        "tier": "moderate",
        "falsification": "FLUCONAZOLE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "GANCICLOVIR",
        "score": 0.7441,
        "rank": 29,
        "tier": "moderate",
        "falsification": "GANCICLOVIR enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "AMOXICILLIN",
        "score": 0.7347,
        "rank": 30,
        "tier": "moderate",
        "falsification": "AMOXICILLIN enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "Fluocinolone Acetonide",
        "score": 0.7317,
        "rank": 31,
        "tier": "moderate",
        "falsification": "Fluocinolone Acetonide enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "LURBINECTEDIN",
        "score": 0.726,
        "rank": 32,
        "tier": "moderate",
        "falsification": "LURBINECTEDIN enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "SERTRALINE",
        "score": 0.7253,
        "rank": 33,
        "tier": "moderate",
        "falsification": "SERTRALINE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "CORTISONE ACETATE",
        "score": 0.7186,
        "rank": 34,
        "tier": "moderate",
        "falsification": "CORTISONE ACETATE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "CLADRIBINE",
        "score": 0.705,
        "rank": 35,
        "tier": "moderate",
        "falsification": "CLADRIBINE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "Fluoxetine",
        "score": 0.6955,
        "rank": 36,
        "tier": "moderate",
        "falsification": "Fluoxetine enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "pembrolizumab",
        "score": 0.6629,
        "rank": 37,
        "tier": "moderate",
        "falsification": "pembrolizumab enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "BAVITUXIMAB",
        "score": 0.6609,
        "rank": 38,
        "tier": "moderate",
        "falsification": "BAVITUXIMAB enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "CABOTEGRAVIR",
        "score": 0.6571,
        "rank": 39,
        "tier": "moderate",
        "falsification": "CABOTEGRAVIR enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "AZELAIC ACID",
        "score": 0.6552,
        "rank": 40,
        "tier": "moderate",
        "falsification": "AZELAIC ACID enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "SOFOSBUVIR",
        "score": 0.6511,
        "rank": 41,
        "tier": "moderate",
        "falsification": "SOFOSBUVIR enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "PYRIMETHAMINE",
        "score": 0.6465,
        "rank": 42,
        "tier": "moderate",
        "falsification": "PYRIMETHAMINE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "AMINOSALICYLIC ACID",
        "score": 0.6462,
        "rank": 43,
        "tier": "moderate",
        "falsification": "AMINOSALICYLIC ACID enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "PAZOPANIB",
        "score": 0.6385,
        "rank": 44,
        "tier": "moderate",
        "falsification": "PAZOPANIB enters Phase 1+ trial for idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "ZIDOVUDINE",
        "score": 0.6369,
        "rank": 45,
        "tier": "moderate",
        "falsification": "ZIDOVUDINE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "FENTANYL",
        "score": 0.6236,
        "rank": 46,
        "tier": "moderate",
        "falsification": "FENTANYL enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "DIDANOSINE",
        "score": 0.6171,
        "rank": 47,
        "tier": "moderate",
        "falsification": "DIDANOSINE enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "Alpelisib",
        "score": 0.6168,
        "rank": 48,
        "tier": "moderate",
        "falsification": "Alpelisib enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "binimetinib",
        "score": 0.6163,
        "rank": 49,
        "tier": "moderate",
        "falsification": "binimetinib enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      },
      {
        "drug_name": "AMINOLEVULINIC ACID",
        "score": 0.6155,
        "rank": 50,
        "tier": "moderate",
        "falsification": "AMINOLEVULINIC ACID enters Phase 1+ trial for Idiopathic pulmonary fibrosis within 5 years"
      }
    ],
    "systemic lupus erythematosus": [
      {
        "drug_name": "METHOTREXATE SODIUM",
        "score": 0.9883,
        "rank": 1,
        "tier": "high",
        "falsification": "METHOTREXATE SODIUM enters Phase 2+ trial for Systemic lupus erythematosus within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "entrectinib",
        "score": 0.9868,
        "rank": 2,
        "tier": "high",
        "falsification": "entrectinib enters Phase 2+ trial for Systemic lupus erythematosus within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "DEXAMETHASONE ACETATE",
        "score": 0.9864,
        "rank": 3,
        "tier": "high",
        "falsification": "DEXAMETHASONE ACETATE enters Phase 2+ trial for Systemic lupus erythematosus within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "prednisolone acetate",
        "score": 0.9847,
        "rank": 4,
        "tier": "high",
        "falsification": "prednisolone acetate enters Phase 2+ trial for Systemic lupus erythematosus within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "ITACITINIB",
        "score": 0.9845,
        "rank": 5,
        "tier": "high",
        "falsification": "ITACITINIB enters Phase 2+ trial for Systemic lupus erythematosus within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "pembrolizumab",
        "score": 0.9833,
        "rank": 6,
        "tier": "high",
        "falsification": "pembrolizumab enters Phase 2+ trial for Systemic lupus erythematosus within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "brigatinib",
        "score": 0.9829,
        "rank": 7,
        "tier": "high",
        "falsification": "brigatinib enters Phase 2+ trial for Systemic lupus erythematosus within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "BUDESONIDE",
        "score": 0.982,
        "rank": 8,
        "tier": "high",
        "falsification": "BUDESONIDE enters Phase 2+ trial for Systemic lupus erythematosus within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "PREDNISOLONE SODIUM PHOSPHATE",
        "score": 0.9806,
        "rank": 9,
        "tier": "high",
        "falsification": "PREDNISOLONE SODIUM PHOSPHATE enters Phase 2+ trial for Systemic lupus erythematosus within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "ERLOTINIB",
        "score": 0.9785,
        "rank": 10,
        "tier": "high",
        "falsification": "ERLOTINIB enters Phase 2+ trial for Systemic lupus erythematosus within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "CARBOPLATIN",
        "score": 0.9776,
        "rank": 11,
        "tier": "moderate",
        "falsification": "CARBOPLATIN enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "nintedanib",
        "score": 0.9769,
        "rank": 12,
        "tier": "moderate",
        "falsification": "nintedanib enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "Gefitinib",
        "score": 0.9764,
        "rank": 13,
        "tier": "moderate",
        "falsification": "Gefitinib enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "REMIBRUTINIB",
        "score": 0.9753,
        "rank": 14,
        "tier": "moderate",
        "falsification": "REMIBRUTINIB enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "FLUTICASONE FUROATE",
        "score": 0.9738,
        "rank": 15,
        "tier": "moderate",
        "falsification": "FLUTICASONE FUROATE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "FLUTICASONE PROPIONATE",
        "score": 0.9705,
        "rank": 16,
        "tier": "moderate",
        "falsification": "FLUTICASONE PROPIONATE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "CRIZOTINIB",
        "score": 0.9701,
        "rank": 17,
        "tier": "moderate",
        "falsification": "CRIZOTINIB enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "ABEMACICLIB",
        "score": 0.9695,
        "rank": 18,
        "tier": "moderate",
        "falsification": "ABEMACICLIB enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "LEUCOVORIN CALCIUM",
        "score": 0.9667,
        "rank": 19,
        "tier": "moderate",
        "falsification": "LEUCOVORIN CALCIUM enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "ERLOTINIB HYDROCHLORIDE",
        "score": 0.9661,
        "rank": 20,
        "tier": "moderate",
        "falsification": "ERLOTINIB HYDROCHLORIDE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "PREDNISOLONE TEBUTATE",
        "score": 0.9649,
        "rank": 21,
        "tier": "moderate",
        "falsification": "PREDNISOLONE TEBUTATE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "PELITINIB",
        "score": 0.964,
        "rank": 22,
        "tier": "moderate",
        "falsification": "PELITINIB enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "ATORVASTATIN CALCIUM",
        "score": 0.9637,
        "rank": 23,
        "tier": "moderate",
        "falsification": "ATORVASTATIN CALCIUM enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "TAMOXIFEN CITRATE",
        "score": 0.959,
        "rank": 24,
        "tier": "moderate",
        "falsification": "TAMOXIFEN CITRATE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "Sulfasalazine",
        "score": 0.9588,
        "rank": 25,
        "tier": "moderate",
        "falsification": "Sulfasalazine enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "DEXAMETHASONE PHOSPHORIC ACID",
        "score": 0.958,
        "rank": 26,
        "tier": "moderate",
        "falsification": "DEXAMETHASONE PHOSPHORIC ACID enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "PREDNISOLONE PHOSPHORIC ACID",
        "score": 0.9576,
        "rank": 27,
        "tier": "moderate",
        "falsification": "PREDNISOLONE PHOSPHORIC ACID enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "nilotinib",
        "score": 0.9576,
        "rank": 28,
        "tier": "moderate",
        "falsification": "nilotinib enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "RIBAVIRIN",
        "score": 0.9559,
        "rank": 29,
        "tier": "moderate",
        "falsification": "RIBAVIRIN enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "BORTEZOMIB",
        "score": 0.955,
        "rank": 30,
        "tier": "moderate",
        "falsification": "BORTEZOMIB enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "peginterferon beta-1a",
        "score": 0.9549,
        "rank": 31,
        "tier": "moderate",
        "falsification": "peginterferon beta-1a enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "DABRAFENIB MESYLATE",
        "score": 0.9441,
        "rank": 32,
        "tier": "moderate",
        "falsification": "DABRAFENIB MESYLATE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "POVORCITINIB",
        "score": 0.9364,
        "rank": 33,
        "tier": "moderate",
        "falsification": "POVORCITINIB enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "ibrutinib",
        "score": 0.9354,
        "rank": 34,
        "tier": "moderate",
        "falsification": "ibrutinib enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "IBUPROFEN",
        "score": 0.9304,
        "rank": 35,
        "tier": "moderate",
        "falsification": "IBUPROFEN enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "LEUCOVORIN",
        "score": 0.9278,
        "rank": 36,
        "tier": "moderate",
        "falsification": "LEUCOVORIN enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "score": 0.9233,
        "rank": 37,
        "tier": "moderate",
        "falsification": "IRINOTECAN HYDROCHLORIDE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "DORAMAPIMOD",
        "score": 0.9214,
        "rank": 38,
        "tier": "moderate",
        "falsification": "DORAMAPIMOD enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "PALBOCICLIB",
        "score": 0.921,
        "rank": 39,
        "tier": "moderate",
        "falsification": "PALBOCICLIB enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "rebastinib",
        "score": 0.92,
        "rank": 40,
        "tier": "moderate",
        "falsification": "rebastinib enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "zanubrutinib",
        "score": 0.9195,
        "rank": 41,
        "tier": "moderate",
        "falsification": "zanubrutinib enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "METHYLPREDNISOLONE ACETATE",
        "score": 0.918,
        "rank": 42,
        "tier": "moderate",
        "falsification": "METHYLPREDNISOLONE ACETATE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "DABRAFENIB",
        "score": 0.9175,
        "rank": 43,
        "tier": "moderate",
        "falsification": "DABRAFENIB enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "Alpelisib",
        "score": 0.9147,
        "rank": 44,
        "tier": "moderate",
        "falsification": "Alpelisib enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "GLATIRAMER ACETATE",
        "score": 0.9116,
        "rank": 45,
        "tier": "moderate",
        "falsification": "GLATIRAMER ACETATE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "NITAZOXANIDE",
        "score": 0.9082,
        "rank": 46,
        "tier": "moderate",
        "falsification": "NITAZOXANIDE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "MYCOPHENOLATE MOFETIL HYDROCHLORIDE",
        "score": 0.8999,
        "rank": 47,
        "tier": "moderate",
        "falsification": "MYCOPHENOLATE MOFETIL HYDROCHLORIDE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "NAPROXEN",
        "score": 0.8954,
        "rank": 48,
        "tier": "moderate",
        "falsification": "NAPROXEN enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "CETIRIZINE",
        "score": 0.8885,
        "rank": 49,
        "tier": "moderate",
        "falsification": "CETIRIZINE enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      },
      {
        "drug_name": "CISPLATIN",
        "score": 0.8864,
        "rank": 50,
        "tier": "moderate",
        "falsification": "CISPLATIN enters Phase 1+ trial for Systemic lupus erythematosus within 5 years"
      }
    ],
    "type 2 diabetes": [
      {
        "drug_name": "LAPATINIB",
        "score": 0.9886,
        "rank": 1,
        "tier": "high",
        "falsification": "LAPATINIB enters Phase 2+ trial for Type 2 diabetes within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "linifanib",
        "score": 0.9799,
        "rank": 2,
        "tier": "high",
        "falsification": "linifanib enters Phase 2+ trial for Type 2 diabetes within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "KW-2449",
        "score": 0.9773,
        "rank": 3,
        "tier": "high",
        "falsification": "KW-2449 enters Phase 2+ trial for Type 2 diabetes within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "SU-014813",
        "score": 0.9671,
        "rank": 4,
        "tier": "high",
        "falsification": "SU-014813 enters Phase 2+ trial for Type 2 diabetes within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "AST-487",
        "score": 0.9646,
        "rank": 5,
        "tier": "high",
        "falsification": "AST-487 enters Phase 2+ trial for Type 2 diabetes within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "BROMOCRIPTINE MESYLATE",
        "score": 0.9595,
        "rank": 6,
        "tier": "high",
        "falsification": "BROMOCRIPTINE MESYLATE enters Phase 2+ trial for type 2 diabetes within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "entrectinib",
        "score": 0.9577,
        "rank": 7,
        "tier": "high",
        "falsification": "entrectinib enters Phase 2+ trial for Type 2 diabetes within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Chlorthalidone",
        "score": 0.9569,
        "rank": 8,
        "tier": "high",
        "falsification": "Chlorthalidone enters Phase 2+ trial for Type 2 diabetes within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "score": 0.9565,
        "rank": 9,
        "tier": "high",
        "falsification": "SUNITINIB MALATE enters Phase 2+ trial for Type 2 diabetes within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "DORAMAPIMOD",
        "score": 0.9549,
        "rank": 10,
        "tier": "high",
        "falsification": "DORAMAPIMOD enters Phase 2+ trial for Type 2 diabetes within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "PELITINIB",
        "score": 0.9548,
        "rank": 11,
        "tier": "moderate",
        "falsification": "PELITINIB enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "FELODIPINE",
        "score": 0.9517,
        "rank": 12,
        "tier": "moderate",
        "falsification": "FELODIPINE enters Phase 1+ trial for type 2 diabetes within 5 years"
      },
      {
        "drug_name": "TACROLIMUS ANHYDROUS",
        "score": 0.9511,
        "rank": 13,
        "tier": "moderate",
        "falsification": "TACROLIMUS ANHYDROUS enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "QUETIAPINE",
        "score": 0.9509,
        "rank": 14,
        "tier": "moderate",
        "falsification": "QUETIAPINE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "SUNITINIB",
        "score": 0.948,
        "rank": 15,
        "tier": "moderate",
        "falsification": "SUNITINIB enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "AMLODIPINE MALEATE",
        "score": 0.9473,
        "rank": 16,
        "tier": "moderate",
        "falsification": "AMLODIPINE MALEATE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "Clozapine",
        "score": 0.9466,
        "rank": 17,
        "tier": "moderate",
        "falsification": "Clozapine enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "HEXACHLOROPHENE",
        "score": 0.9454,
        "rank": 18,
        "tier": "moderate",
        "falsification": "HEXACHLOROPHENE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "CANDESARTAN CILEXETIL",
        "score": 0.9453,
        "rank": 19,
        "tier": "moderate",
        "falsification": "CANDESARTAN CILEXETIL enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "brigatinib",
        "score": 0.9452,
        "rank": 20,
        "tier": "moderate",
        "falsification": "brigatinib enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "PAROXETINE",
        "score": 0.9444,
        "rank": 21,
        "tier": "moderate",
        "falsification": "PAROXETINE enters Phase 1+ trial for type 2 diabetes within 5 years"
      },
      {
        "drug_name": "ARIPIPRAZOLE LAUROXIL",
        "score": 0.9444,
        "rank": 22,
        "tier": "moderate",
        "falsification": "ARIPIPRAZOLE LAUROXIL enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "OLMUTINIB",
        "score": 0.9412,
        "rank": 23,
        "tier": "moderate",
        "falsification": "OLMUTINIB enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "DOXAZOSIN MESYLATE",
        "score": 0.9408,
        "rank": 24,
        "tier": "moderate",
        "falsification": "DOXAZOSIN MESYLATE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "Celecoxib",
        "score": 0.9382,
        "rank": 25,
        "tier": "moderate",
        "falsification": "Celecoxib enters Phase 1+ trial for type 2 diabetes within 5 years"
      },
      {
        "drug_name": "Imatinib Mesylate",
        "score": 0.9367,
        "rank": 26,
        "tier": "moderate",
        "falsification": "Imatinib Mesylate enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "OLANZAPINE",
        "score": 0.936,
        "rank": 27,
        "tier": "moderate",
        "falsification": "OLANZAPINE enters Phase 1+ trial for type 2 diabetes within 5 years"
      },
      {
        "drug_name": "AMLODIPINE BENZOATE",
        "score": 0.935,
        "rank": 28,
        "tier": "moderate",
        "falsification": "AMLODIPINE BENZOATE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "OMEPRAZOLE",
        "score": 0.9344,
        "rank": 29,
        "tier": "moderate",
        "falsification": "OMEPRAZOLE enters Phase 1+ trial for type 2 diabetes within 5 years"
      },
      {
        "drug_name": "Risperidone",
        "score": 0.9322,
        "rank": 30,
        "tier": "moderate",
        "falsification": "Risperidone enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "CRIZOTINIB",
        "score": 0.9294,
        "rank": 31,
        "tier": "moderate",
        "falsification": "CRIZOTINIB enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "DILTIAZEM MALATE",
        "score": 0.9278,
        "rank": 32,
        "tier": "moderate",
        "falsification": "DILTIAZEM MALATE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "TICAGRELOR",
        "score": 0.9268,
        "rank": 33,
        "tier": "moderate",
        "falsification": "TICAGRELOR enters Phase 1+ trial for type 2 diabetes within 5 years"
      },
      {
        "drug_name": "OLANZAPINE",
        "score": 0.9266,
        "rank": 34,
        "tier": "moderate",
        "falsification": "OLANZAPINE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "Quetiapine Fumarate",
        "score": 0.9259,
        "rank": 35,
        "tier": "moderate",
        "falsification": "Quetiapine Fumarate enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "DILTIAZEM HYDROCHLORIDE",
        "score": 0.9252,
        "rank": 36,
        "tier": "moderate",
        "falsification": "DILTIAZEM HYDROCHLORIDE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "EFAVIRENZ",
        "score": 0.9245,
        "rank": 37,
        "tier": "moderate",
        "falsification": "EFAVIRENZ enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "Gemfibrozil",
        "score": 0.9234,
        "rank": 38,
        "tier": "moderate",
        "falsification": "Gemfibrozil enters Phase 1+ trial for type 2 diabetes within 5 years"
      },
      {
        "drug_name": "ETRIPAMIL",
        "score": 0.9227,
        "rank": 39,
        "tier": "moderate",
        "falsification": "ETRIPAMIL enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "fedratinib",
        "score": 0.9219,
        "rank": 40,
        "tier": "moderate",
        "falsification": "fedratinib enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "OSI-632",
        "score": 0.9212,
        "rank": 41,
        "tier": "moderate",
        "falsification": "OSI-632 enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "ALOGLIPTIN BENZOATE",
        "score": 0.9197,
        "rank": 42,
        "tier": "moderate",
        "falsification": "ALOGLIPTIN BENZOATE enters Phase 1+ trial for type 2 diabetes within 5 years"
      },
      {
        "drug_name": "EBASTINE",
        "score": 0.9188,
        "rank": 43,
        "tier": "moderate",
        "falsification": "EBASTINE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "AMIODARONE",
        "score": 0.9187,
        "rank": 44,
        "tier": "moderate",
        "falsification": "AMIODARONE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "HYDROXYZINE",
        "score": 0.9159,
        "rank": 45,
        "tier": "moderate",
        "falsification": "HYDROXYZINE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "Sulfasalazine",
        "score": 0.9151,
        "rank": 46,
        "tier": "moderate",
        "falsification": "Sulfasalazine enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "PRAZOSIN HYDROCHLORIDE",
        "score": 0.9127,
        "rank": 47,
        "tier": "moderate",
        "falsification": "PRAZOSIN HYDROCHLORIDE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "Lansoprazole",
        "score": 0.9116,
        "rank": 48,
        "tier": "moderate",
        "falsification": "Lansoprazole enters Phase 1+ trial for type 2 diabetes within 5 years"
      },
      {
        "drug_name": "deucravacitinib",
        "score": 0.9103,
        "rank": 49,
        "tier": "moderate",
        "falsification": "deucravacitinib enters Phase 1+ trial for Type 2 diabetes within 5 years"
      },
      {
        "drug_name": "RALOXIFENE",
        "score": 0.903,
        "rank": 50,
        "tier": "moderate",
        "falsification": "RALOXIFENE enters Phase 1+ trial for Type 2 diabetes within 5 years"
      }
    ],
    "ulcerative colitis": [
      {
        "drug_name": "GOLIDOCITINIB",
        "score": 0.9914,
        "rank": 1,
        "tier": "high",
        "falsification": "GOLIDOCITINIB enters Phase 2+ trial for Ulcerative colitis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "METHOTREXATE SODIUM",
        "score": 0.9914,
        "rank": 2,
        "tier": "high",
        "falsification": "METHOTREXATE SODIUM enters Phase 2+ trial for Ulcerative colitis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "LOMEDEUCITINIB",
        "score": 0.9911,
        "rank": 3,
        "tier": "high",
        "falsification": "LOMEDEUCITINIB enters Phase 2+ trial for Ulcerative colitis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "FLUTICASONE FUROATE",
        "score": 0.9889,
        "rank": 4,
        "tier": "high",
        "falsification": "FLUTICASONE FUROATE enters Phase 2+ trial for Ulcerative colitis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "entrectinib",
        "score": 0.9866,
        "rank": 5,
        "tier": "high",
        "falsification": "entrectinib enters Phase 2+ trial for Ulcerative colitis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "abrocitinib",
        "score": 0.9865,
        "rank": 6,
        "tier": "high",
        "falsification": "abrocitinib enters Phase 2+ trial for Ulcerative colitis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Diclofenac",
        "score": 0.9851,
        "rank": 7,
        "tier": "high",
        "falsification": "Diclofenac enters Phase 2+ trial for Ulcerative colitis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "FLUTICASONE PROPIONATE",
        "score": 0.985,
        "rank": 8,
        "tier": "high",
        "falsification": "FLUTICASONE PROPIONATE enters Phase 2+ trial for Ulcerative colitis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "MYCOPHENOLATE MOFETIL",
        "score": 0.9834,
        "rank": 9,
        "tier": "high",
        "falsification": "MYCOPHENOLATE MOFETIL enters Phase 2+ trial for Ulcerative colitis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "INFLUENZA VIRUS VACCINE",
        "score": 0.9832,
        "rank": 10,
        "tier": "high",
        "falsification": "INFLUENZA VIRUS VACCINE enters Phase 2+ trial for Ulcerative colitis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Imatinib Mesylate",
        "score": 0.9795,
        "rank": 11,
        "tier": "moderate",
        "falsification": "Imatinib Mesylate enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "Atorvastatin",
        "score": 0.9791,
        "rank": 12,
        "tier": "moderate",
        "falsification": "Atorvastatin enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "TRIAMCINOLONE",
        "score": 0.9763,
        "rank": 13,
        "tier": "moderate",
        "falsification": "TRIAMCINOLONE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "GANCICLOVIR",
        "score": 0.9743,
        "rank": 14,
        "tier": "moderate",
        "falsification": "GANCICLOVIR enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "Digoxin",
        "score": 0.9738,
        "rank": 15,
        "tier": "moderate",
        "falsification": "Digoxin enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "POVORCITINIB",
        "score": 0.9729,
        "rank": 16,
        "tier": "moderate",
        "falsification": "POVORCITINIB enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "CRIZOTINIB",
        "score": 0.9721,
        "rank": 17,
        "tier": "moderate",
        "falsification": "CRIZOTINIB enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "PYRAZINAMIDE",
        "score": 0.9714,
        "rank": 18,
        "tier": "moderate",
        "falsification": "PYRAZINAMIDE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "score": 0.9712,
        "rank": 19,
        "tier": "moderate",
        "falsification": "SORAFENIB TOSYLATE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "Celecoxib",
        "score": 0.97,
        "rank": 20,
        "tier": "moderate",
        "falsification": "Celecoxib enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "LEUCOVORIN",
        "score": 0.9665,
        "rank": 21,
        "tier": "moderate",
        "falsification": "LEUCOVORIN enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "pembrolizumab",
        "score": 0.9664,
        "rank": 22,
        "tier": "moderate",
        "falsification": "pembrolizumab enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "DEURUXOLITINIB",
        "score": 0.9622,
        "rank": 23,
        "tier": "moderate",
        "falsification": "DEURUXOLITINIB enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "brigatinib",
        "score": 0.9607,
        "rank": 24,
        "tier": "moderate",
        "falsification": "brigatinib enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "FLUOROURACIL",
        "score": 0.9607,
        "rank": 25,
        "tier": "moderate",
        "falsification": "FLUOROURACIL enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "GLATIRAMER ACETATE",
        "score": 0.959,
        "rank": 26,
        "tier": "moderate",
        "falsification": "GLATIRAMER ACETATE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "ISONIAZID",
        "score": 0.9585,
        "rank": 27,
        "tier": "moderate",
        "falsification": "ISONIAZID enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "Gefitinib",
        "score": 0.9575,
        "rank": 28,
        "tier": "moderate",
        "falsification": "Gefitinib enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "prednisolone acetate",
        "score": 0.9561,
        "rank": 29,
        "tier": "moderate",
        "falsification": "prednisolone acetate enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "DAPSONE",
        "score": 0.9545,
        "rank": 30,
        "tier": "moderate",
        "falsification": "DAPSONE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "Piroxicam",
        "score": 0.9538,
        "rank": 31,
        "tier": "moderate",
        "falsification": "Piroxicam enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "Paclitaxel",
        "score": 0.9531,
        "rank": 32,
        "tier": "moderate",
        "falsification": "Paclitaxel enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "ROVADICITINIB",
        "score": 0.9519,
        "rank": 33,
        "tier": "moderate",
        "falsification": "ROVADICITINIB enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "EFAVIRENZ",
        "score": 0.9517,
        "rank": 34,
        "tier": "moderate",
        "falsification": "EFAVIRENZ enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "IBUPROFEN",
        "score": 0.9482,
        "rank": 35,
        "tier": "moderate",
        "falsification": "IBUPROFEN enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "PAZOPANIB HYDROCHLORIDE",
        "score": 0.9456,
        "rank": 36,
        "tier": "moderate",
        "falsification": "PAZOPANIB HYDROCHLORIDE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "Ketorolac Tromethamine",
        "score": 0.9411,
        "rank": 37,
        "tier": "moderate",
        "falsification": "Ketorolac Tromethamine enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "GUSACITINIB HYDROCHLORIDE",
        "score": 0.9396,
        "rank": 38,
        "tier": "moderate",
        "falsification": "GUSACITINIB HYDROCHLORIDE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "MOMELOTINIB DIHYDROCHLORIDE",
        "score": 0.9375,
        "rank": 39,
        "tier": "moderate",
        "falsification": "MOMELOTINIB DIHYDROCHLORIDE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "PUMECITINIB",
        "score": 0.933,
        "rank": 40,
        "tier": "moderate",
        "falsification": "PUMECITINIB enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "ABEMACICLIB",
        "score": 0.9284,
        "rank": 41,
        "tier": "moderate",
        "falsification": "ABEMACICLIB enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "KETOROLAC",
        "score": 0.9281,
        "rank": 42,
        "tier": "moderate",
        "falsification": "KETOROLAC enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "ITACITINIB ADIPATE",
        "score": 0.9269,
        "rank": 43,
        "tier": "moderate",
        "falsification": "ITACITINIB ADIPATE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "DICLOFENAC POTASSIUM",
        "score": 0.9244,
        "rank": 44,
        "tier": "moderate",
        "falsification": "DICLOFENAC POTASSIUM enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "LAPATINIB DITOSYLATE",
        "score": 0.9223,
        "rank": 45,
        "tier": "moderate",
        "falsification": "LAPATINIB DITOSYLATE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "IFIDANCITINIB",
        "score": 0.9219,
        "rank": 46,
        "tier": "moderate",
        "falsification": "IFIDANCITINIB enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "NICARDIPINE HYDROCHLORIDE",
        "score": 0.9141,
        "rank": 47,
        "tier": "moderate",
        "falsification": "NICARDIPINE HYDROCHLORIDE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "TRIMETHOPRIM",
        "score": 0.9116,
        "rank": 48,
        "tier": "moderate",
        "falsification": "TRIMETHOPRIM enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "ERLOTINIB HYDROCHLORIDE",
        "score": 0.911,
        "rank": 49,
        "tier": "moderate",
        "falsification": "ERLOTINIB HYDROCHLORIDE enters Phase 1+ trial for Ulcerative colitis within 5 years"
      },
      {
        "drug_name": "IMATINIB",
        "score": 0.911,
        "rank": 50,
        "tier": "moderate",
        "falsification": "IMATINIB enters Phase 1+ trial for Ulcerative colitis within 5 years"
      }
    ],
    "amyotrophic lateral sclerosis": [
      {
        "drug_name": "Lidocaine",
        "score": 0.9713,
        "rank": 1,
        "tier": "high",
        "falsification": "Lidocaine enters Phase 2+ trial for amyotrophic lateral sclerosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Zonisamide",
        "score": 0.9648,
        "rank": 2,
        "tier": "high",
        "falsification": "Zonisamide enters Phase 2+ trial for amyotrophic lateral sclerosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "KETOCONAZOLE",
        "score": 0.9606,
        "rank": 3,
        "tier": "high",
        "falsification": "KETOCONAZOLE enters Phase 2+ trial for amyotrophic lateral sclerosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Haloperidol",
        "score": 0.9431,
        "rank": 4,
        "tier": "high",
        "falsification": "Haloperidol enters Phase 2+ trial for amyotrophic lateral sclerosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Risperidone",
        "score": 0.8918,
        "rank": 5,
        "tier": "high",
        "falsification": "Risperidone enters Phase 2+ trial for amyotrophic lateral sclerosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Quetiapine Fumarate",
        "score": 0.8554,
        "rank": 6,
        "tier": "high",
        "falsification": "Quetiapine Fumarate enters Phase 2+ trial for amyotrophic lateral sclerosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "PHENYTOIN",
        "score": 0.842,
        "rank": 7,
        "tier": "high",
        "falsification": "PHENYTOIN enters Phase 2+ trial for amyotrophic lateral sclerosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "RUFINAMIDE",
        "score": 0.842,
        "rank": 8,
        "tier": "high",
        "falsification": "RUFINAMIDE enters Phase 2+ trial for amyotrophic lateral sclerosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Prochlorperazine",
        "score": 0.837,
        "rank": 9,
        "tier": "high",
        "falsification": "Prochlorperazine enters Phase 2+ trial for amyotrophic lateral sclerosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Duloxetine Hydrochloride",
        "score": 0.8224,
        "rank": 10,
        "tier": "high",
        "falsification": "Duloxetine Hydrochloride enters Phase 2+ trial for amyotrophic lateral sclerosis within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Aripiprazole",
        "score": 0.8218,
        "rank": 11,
        "tier": "moderate",
        "falsification": "Aripiprazole enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Bupivacaine",
        "score": 0.793,
        "rank": 12,
        "tier": "moderate",
        "falsification": "Bupivacaine enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "TRAZODONE",
        "score": 0.7918,
        "rank": 13,
        "tier": "moderate",
        "falsification": "TRAZODONE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "TRORILUZOLE",
        "score": 0.7564,
        "rank": 14,
        "tier": "moderate",
        "falsification": "TRORILUZOLE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Perphenazine",
        "score": 0.7562,
        "rank": 15,
        "tier": "moderate",
        "falsification": "Perphenazine enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Indomethacin",
        "score": 0.7442,
        "rank": 16,
        "tier": "moderate",
        "falsification": "Indomethacin enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "LAMOTRIGINE",
        "score": 0.7438,
        "rank": 17,
        "tier": "moderate",
        "falsification": "LAMOTRIGINE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Diclofenac",
        "score": 0.7359,
        "rank": 18,
        "tier": "moderate",
        "falsification": "Diclofenac enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Doxazosin",
        "score": 0.7153,
        "rank": 19,
        "tier": "moderate",
        "falsification": "Doxazosin enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "ROPIVACAINE HYDROCHLORIDE",
        "score": 0.7107,
        "rank": 20,
        "tier": "moderate",
        "falsification": "ROPIVACAINE HYDROCHLORIDE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "LIDOCAINE HYDROCHLORIDE",
        "score": 0.6833,
        "rank": 21,
        "tier": "moderate",
        "falsification": "LIDOCAINE HYDROCHLORIDE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "LURASIDONE HYDROCHLORIDE",
        "score": 0.6689,
        "rank": 22,
        "tier": "moderate",
        "falsification": "LURASIDONE HYDROCHLORIDE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "CHLORPROMAZINE",
        "score": 0.6425,
        "rank": 23,
        "tier": "moderate",
        "falsification": "CHLORPROMAZINE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Clozapine",
        "score": 0.6388,
        "rank": 24,
        "tier": "moderate",
        "falsification": "Clozapine enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Glyburide",
        "score": 0.6277,
        "rank": 25,
        "tier": "moderate",
        "falsification": "Glyburide enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "ESCITALOPRAM",
        "score": 0.615,
        "rank": 26,
        "tier": "moderate",
        "falsification": "ESCITALOPRAM enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "FLECAINIDE ACETATE",
        "score": 0.6105,
        "rank": 27,
        "tier": "moderate",
        "falsification": "FLECAINIDE ACETATE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "brexpiprazole",
        "score": 0.6056,
        "rank": 28,
        "tier": "moderate",
        "falsification": "brexpiprazole enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "ziprasidone",
        "score": 0.6011,
        "rank": 29,
        "tier": "moderate",
        "falsification": "ziprasidone enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "PALIPERIDONE",
        "score": 0.5946,
        "rank": 30,
        "tier": "moderate",
        "falsification": "PALIPERIDONE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "QUETIAPINE",
        "score": 0.5877,
        "rank": 31,
        "tier": "moderate",
        "falsification": "QUETIAPINE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Prazosin",
        "score": 0.5874,
        "rank": 32,
        "tier": "moderate",
        "falsification": "Prazosin enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "ROPIVACAINE",
        "score": 0.5873,
        "rank": 33,
        "tier": "moderate",
        "falsification": "ROPIVACAINE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "FENTANYL",
        "score": 0.5572,
        "rank": 34,
        "tier": "moderate",
        "falsification": "FENTANYL enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "IBUPROFEN",
        "score": 0.5571,
        "rank": 35,
        "tier": "moderate",
        "falsification": "IBUPROFEN enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Fluoxetine",
        "score": 0.5555,
        "rank": 36,
        "tier": "moderate",
        "falsification": "Fluoxetine enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "PROCAINE HYDROCHLORIDE",
        "score": 0.5485,
        "rank": 37,
        "tier": "moderate",
        "falsification": "PROCAINE HYDROCHLORIDE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Citalopram",
        "score": 0.5416,
        "rank": 38,
        "tier": "moderate",
        "falsification": "Citalopram enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "ZIPRASIDONE HYDROCHLORIDE",
        "score": 0.5311,
        "rank": 39,
        "tier": "moderate",
        "falsification": "ZIPRASIDONE HYDROCHLORIDE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "CRIZOTINIB",
        "score": 0.5297,
        "rank": 40,
        "tier": "moderate",
        "falsification": "CRIZOTINIB enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Pantoprazole",
        "score": 0.5261,
        "rank": 41,
        "tier": "moderate",
        "falsification": "Pantoprazole enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "SERTRALINE",
        "score": 0.5232,
        "rank": 42,
        "tier": "moderate",
        "falsification": "SERTRALINE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "KETOROLAC",
        "score": 0.523,
        "rank": 43,
        "tier": "moderate",
        "falsification": "KETOROLAC enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "score": 0.5121,
        "rank": 44,
        "tier": "moderate",
        "falsification": "IRINOTECAN HYDROCHLORIDE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Alpelisib",
        "score": 0.5045,
        "rank": 45,
        "tier": "moderate",
        "falsification": "Alpelisib enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "PROPARACAINE HYDROCHLORIDE",
        "score": 0.5034,
        "rank": 46,
        "tier": "moderate",
        "falsification": "PROPARACAINE HYDROCHLORIDE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "PAROXETINE",
        "score": 0.5007,
        "rank": 47,
        "tier": "moderate",
        "falsification": "PAROXETINE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Diphenhydramine",
        "score": 0.4867,
        "rank": 48,
        "tier": "moderate",
        "falsification": "Diphenhydramine enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "CARBAMAZEPINE",
        "score": 0.4811,
        "rank": 49,
        "tier": "moderate",
        "falsification": "CARBAMAZEPINE enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      },
      {
        "drug_name": "Orphenadrine",
        "score": 0.4669,
        "rank": 50,
        "tier": "moderate",
        "falsification": "Orphenadrine enters Phase 1+ trial for amyotrophic lateral sclerosis within 5 years"
      }
    ],
    "triple negative breast cancer": [
      {
        "drug_name": "BICALUTAMIDE",
        "score": 0.9887,
        "rank": 1,
        "tier": "high",
        "falsification": "BICALUTAMIDE enters Phase 2+ trial for triple negative breast cancer within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "ABEMACICLIB",
        "score": 0.9884,
        "rank": 2,
        "tier": "high",
        "falsification": "ABEMACICLIB enters Phase 2+ trial for triple negative breast cancer within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Alpelisib",
        "score": 0.9778,
        "rank": 3,
        "tier": "high",
        "falsification": "Alpelisib enters Phase 2+ trial for triple negative breast cancer within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "PREDNISONE",
        "score": 0.975,
        "rank": 4,
        "tier": "high",
        "falsification": "PREDNISONE enters Phase 2+ trial for triple negative breast cancer within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "ERIBULIN MESYLATE",
        "score": 0.9692,
        "rank": 5,
        "tier": "high",
        "falsification": "ERIBULIN MESYLATE enters Phase 2+ trial for triple negative breast cancer within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "ERLOTINIB HYDROCHLORIDE",
        "score": 0.9675,
        "rank": 6,
        "tier": "high",
        "falsification": "ERLOTINIB HYDROCHLORIDE enters Phase 2+ trial for triple negative breast cancer within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "MIFEPRISTONE",
        "score": 0.9645,
        "rank": 7,
        "tier": "high",
        "falsification": "MIFEPRISTONE enters Phase 2+ trial for triple negative breast cancer within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "VINCRISTINE",
        "score": 0.9521,
        "rank": 8,
        "tier": "high",
        "falsification": "VINCRISTINE enters Phase 2+ trial for triple negative breast cancer within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "Celecoxib",
        "score": 0.9382,
        "rank": 9,
        "tier": "high",
        "falsification": "Celecoxib enters Phase 2+ trial for triple negative breast cancer within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "DOXORUBICIN HYDROCHLORIDE",
        "score": 0.935,
        "rank": 10,
        "tier": "high",
        "falsification": "DOXORUBICIN HYDROCHLORIDE enters Phase 2+ trial for triple negative breast cancer within 3 years, OR receives FDA approval"
      },
      {
        "drug_name": "apalutamide",
        "score": 0.927,
        "rank": 11,
        "tier": "moderate",
        "falsification": "apalutamide enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "VINCRISTINE SULFATE",
        "score": 0.925,
        "rank": 12,
        "tier": "moderate",
        "falsification": "VINCRISTINE SULFATE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "DOCETAXEL ANHYDROUS",
        "score": 0.9186,
        "rank": 13,
        "tier": "moderate",
        "falsification": "DOCETAXEL ANHYDROUS enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "score": 0.9014,
        "rank": 14,
        "tier": "moderate",
        "falsification": "IRINOTECAN HYDROCHLORIDE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "CRIZOTINIB",
        "score": 0.8842,
        "rank": 15,
        "tier": "moderate",
        "falsification": "CRIZOTINIB enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "PEMETREXED DISODIUM",
        "score": 0.883,
        "rank": 16,
        "tier": "moderate",
        "falsification": "PEMETREXED DISODIUM enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "ibrutinib",
        "score": 0.8766,
        "rank": 17,
        "tier": "moderate",
        "falsification": "ibrutinib enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "ESTRADIOL",
        "score": 0.8668,
        "rank": 18,
        "tier": "moderate",
        "falsification": "ESTRADIOL enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "DEXAMETHASONE ACETATE",
        "score": 0.8648,
        "rank": 19,
        "tier": "moderate",
        "falsification": "DEXAMETHASONE ACETATE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "Indomethacin",
        "score": 0.8525,
        "rank": 20,
        "tier": "moderate",
        "falsification": "Indomethacin enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "IXABEPILONE",
        "score": 0.8497,
        "rank": 21,
        "tier": "moderate",
        "falsification": "IXABEPILONE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "VINORELBINE TARTRATE",
        "score": 0.8484,
        "rank": 22,
        "tier": "moderate",
        "falsification": "VINORELBINE TARTRATE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "GEMCITABINE HYDROCHLORIDE",
        "score": 0.8316,
        "rank": 23,
        "tier": "moderate",
        "falsification": "GEMCITABINE HYDROCHLORIDE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "cabazitaxel",
        "score": 0.8171,
        "rank": 24,
        "tier": "moderate",
        "falsification": "cabazitaxel enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "Flutamide",
        "score": 0.8107,
        "rank": 25,
        "tier": "moderate",
        "falsification": "Flutamide enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "TAMOXIFEN CITRATE",
        "score": 0.8051,
        "rank": 26,
        "tier": "moderate",
        "falsification": "TAMOXIFEN CITRATE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "SELUMETINIB",
        "score": 0.7858,
        "rank": 27,
        "tier": "moderate",
        "falsification": "SELUMETINIB enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "VINBLASTINE SULFATE",
        "score": 0.7799,
        "rank": 28,
        "tier": "moderate",
        "falsification": "VINBLASTINE SULFATE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "NILUTAMIDE",
        "score": 0.75,
        "rank": 29,
        "tier": "moderate",
        "falsification": "NILUTAMIDE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "Gefitinib",
        "score": 0.7136,
        "rank": 30,
        "tier": "moderate",
        "falsification": "Gefitinib enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "Colchicine",
        "score": 0.7124,
        "rank": 31,
        "tier": "moderate",
        "falsification": "Colchicine enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "DEXAMETHASONE SODIUM PHOSPHATE",
        "score": 0.6983,
        "rank": 32,
        "tier": "moderate",
        "falsification": "DEXAMETHASONE SODIUM PHOSPHATE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "SUNITINIB",
        "score": 0.6701,
        "rank": 33,
        "tier": "moderate",
        "falsification": "SUNITINIB enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "Imatinib Mesylate",
        "score": 0.6539,
        "rank": 34,
        "tier": "moderate",
        "falsification": "Imatinib Mesylate enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "RUXOLITINIB PHOSPHATE",
        "score": 0.5938,
        "rank": 35,
        "tier": "moderate",
        "falsification": "RUXOLITINIB PHOSPHATE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "Thalidomide",
        "score": 0.5919,
        "rank": 36,
        "tier": "moderate",
        "falsification": "Thalidomide enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "score": 0.5696,
        "rank": 37,
        "tier": "moderate",
        "falsification": "SUNITINIB MALATE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "LENALIDOMIDE",
        "score": 0.5676,
        "rank": 38,
        "tier": "moderate",
        "falsification": "LENALIDOMIDE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "ANASTROZOLE",
        "score": 0.5089,
        "rank": 39,
        "tier": "moderate",
        "falsification": "ANASTROZOLE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "LEVONORGESTREL",
        "score": 0.4943,
        "rank": 40,
        "tier": "moderate",
        "falsification": "LEVONORGESTREL enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "zanubrutinib",
        "score": 0.4758,
        "rank": 41,
        "tier": "moderate",
        "falsification": "zanubrutinib enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "TESTOSTERONE",
        "score": 0.4656,
        "rank": 42,
        "tier": "moderate",
        "falsification": "TESTOSTERONE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "PACLITAXEL POLIGLUMEX",
        "score": 0.4576,
        "rank": 43,
        "tier": "moderate",
        "falsification": "PACLITAXEL POLIGLUMEX enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "LEFLUNOMIDE",
        "score": 0.4377,
        "rank": 44,
        "tier": "moderate",
        "falsification": "LEFLUNOMIDE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "LAPATINIB DITOSYLATE",
        "score": 0.4225,
        "rank": 45,
        "tier": "moderate",
        "falsification": "LAPATINIB DITOSYLATE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "IBUPROFEN",
        "score": 0.4142,
        "rank": 46,
        "tier": "moderate",
        "falsification": "IBUPROFEN enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "score": 0.407,
        "rank": 47,
        "tier": "moderate",
        "falsification": "SORAFENIB TOSYLATE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "Aspirin",
        "score": 0.3459,
        "rank": 48,
        "tier": "moderate",
        "falsification": "Aspirin enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "METHOTREXATE SODIUM",
        "score": 0.3369,
        "rank": 49,
        "tier": "moderate",
        "falsification": "METHOTREXATE SODIUM enters Phase 1+ trial for triple negative breast cancer within 5 years"
      },
      {
        "drug_name": "PAZOPANIB HYDROCHLORIDE",
        "score": 0.3158,
        "rank": 50,
        "tier": "moderate",
        "falsification": "PAZOPANIB HYDROCHLORIDE enters Phase 1+ trial for triple negative breast cancer within 5 years"
      }
    ]
  },
  "outcomes_by_disease": {
    "glioblastoma": [
      {
        "drug_name": "DOVITINIB",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "DOVITINIB",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "DOXORUBICIN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "IMATINIB",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": null,
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": null,
        "source": "ctgov"
      },
      {
        "drug_name": "LEUCOVORIN CALCIUM",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "RAMUCIRUMAB",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "Thioguanine",
        "type": "phase_advanced",
        "date": null,
        "source": "chembl"
      },
      {
        "drug_name": "DOXORUBICIN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "1994-05-01",
        "source": "ctgov"
      },
      {
        "drug_name": "TAMOXIFEN CITRATE",
        "type": "phase_advanced",
        "date": "1994-05-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "1997-09-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "1997-09-01",
        "source": "ctgov"
      },
      {
        "drug_name": "LEFLUNOMIDE",
        "type": "phase_advanced",
        "date": "1998-02-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "1998-07-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "1998-07-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "1998-07-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "1998-07-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "1999-05-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "1999-05-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2000-08-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2000-08-01",
        "source": "ctgov"
      },
      {
        "drug_name": "TAMOXIFEN CITRATE",
        "type": "phase_advanced",
        "date": "2000-12-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2001-01-05",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2001-01-05",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2002-03-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2002-03-01",
        "source": "ctgov"
      },
      {
        "drug_name": "DOCETAXEL",
        "type": "phase_advanced",
        "date": "2002-07-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2002-07-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2002-07-01",
        "source": "ctgov"
      },
      {
        "drug_name": "TAMOXIFEN CITRATE",
        "type": "phase_advanced",
        "date": "2003-05-01",
        "source": "ctgov"
      },
      {
        "drug_name": "Thioguanine",
        "type": "phase_advanced",
        "date": "2003-09-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2004-11-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2004-11-01",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2004-12-01",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2004-12-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2005-05-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2005-05-01",
        "source": "ctgov"
      },
      {
        "drug_name": "LEUCOVORIN CALCIUM",
        "type": "phase_advanced",
        "date": "2005-07-12",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2006-03-24",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2006-03-24",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2006-04-01",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2006-04-01",
        "source": "ctgov"
      },
      {
        "drug_name": "TAMOXIFEN CITRATE",
        "type": "phase_advanced",
        "date": "2006-12-01",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2007-01-01",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2007-01-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2007-03-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2007-03-01",
        "source": "ctgov"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "type": "phase_advanced",
        "date": "2007-03-01",
        "source": "ctgov"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "type": "phase_advanced",
        "date": "2007-03-01",
        "source": "ctgov"
      },
      {
        "drug_name": "DACARBAZINE",
        "type": "phase_advanced",
        "date": "2007-05-01",
        "source": "ctgov"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "type": "phase_advanced",
        "date": "2007-06-01",
        "source": "ctgov"
      },
      {
        "drug_name": "SUNITINIB MALATE",
        "type": "phase_advanced",
        "date": "2007-06-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2007-10-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2007-10-01",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2008-09-01",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2008-09-01",
        "source": "ctgov"
      },
      {
        "drug_name": "RAMUCIRUMAB",
        "type": "phase_advanced",
        "date": "2010-07-01",
        "source": "ctgov"
      },
      {
        "drug_name": "BUSULFAN",
        "type": "status_transition",
        "date": "2012-08-01",
        "source": "ctgov"
      },
      {
        "drug_name": "DOVITINIB",
        "type": "phase_advanced",
        "date": "2012-12-20",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2013-04-11",
        "source": "ctgov"
      },
      {
        "drug_name": "SORAFENIB TOSYLATE",
        "type": "phase_advanced",
        "date": "2013-04-11",
        "source": "ctgov"
      },
      {
        "drug_name": "DOVITINIB",
        "type": "phase_advanced",
        "date": "2013-10-01",
        "source": "ctgov"
      },
      {
        "drug_name": "LEUCOVORIN CALCIUM",
        "type": "phase_advanced",
        "date": "2014-10-07",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "status_transition",
        "date": "2014-12-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "status_transition",
        "date": "2014-12-01",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2016-03-07",
        "source": "ctgov"
      },
      {
        "drug_name": "IRINOTECAN HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2016-03-07",
        "source": "ctgov"
      }
    ],
    "triple negative breast cancer": [
      {
        "drug_name": "ERLOTINIB HYDROCHLORIDE",
        "type": "phase_advanced",
        "date": "2009-09-01",
        "source": "ctgov"
      },
      {
        "drug_name": "Indomethacin",
        "type": "phase_advanced",
        "date": "2017-02-09",
        "source": "ctgov"
      },
      {
        "drug_name": "VINORELBINE TARTRATE",
        "type": "phase_advanced",
        "date": "2017-06-14",
        "source": "ctgov"
      },
      {
        "drug_name": "BICALUTAMIDE",
        "type": "phase_advanced",
        "date": "2018-05-07",
        "source": "ctgov"
      },
      {
        "drug_name": "CRIZOTINIB",
        "type": "phase_advanced",
        "date": "2019-05-09",
        "source": "ctgov"
      },
      {
        "drug_name": "ERIBULIN MESYLATE",
        "type": "phase_advanced",
        "date": "2020-06-01",
        "source": "ctgov"
      },
      {
        "drug_name": "PREDNISONE",
        "type": "phase_advanced",
        "date": "2021-02-10",
        "source": "ctgov"
      },
      {
        "drug_name": "ERIBULIN MESYLATE",
        "type": "phase_advanced",
        "date": "2021-06-01",
        "source": "ctgov"
      },
      {
        "drug_name": "ABEMACICLIB",
        "type": "phase_advanced",
        "date": "2026-01-01",
        "source": "ctgov"
      },
      {
        "drug_name": "LENALIDOMIDE",
        "type": "first_trial_seen",
        "date": "2026-06-01",
        "source": "ctgov"
      }
    ],
    "amyotrophic lateral sclerosis": [
      {
        "drug_name": "ESCITALOPRAM",
        "type": "phase_advanced",
        "date": "2009-07-01",
        "source": "ctgov"
      },
      {
        "drug_name": "TRAZODONE",
        "type": "phase_advanced",
        "date": "2020-02-27",
        "source": "ctgov"
      }
    ],
    "type 2 diabetes": [
      {
        "drug_name": "CANDESARTAN CILEXETIL",
        "type": "phase_advanced",
        "date": "2001-08-01",
        "source": "ctgov"
      },
      {
        "drug_name": "BROMOCRIPTINE MESYLATE",
        "type": "phase_advanced",
        "date": "2005-02-01",
        "source": "ctgov"
      },
      {
        "drug_name": "BROMOCRIPTINE MESYLATE",
        "type": "phase_advanced",
        "date": "2014-01-01",
        "source": "ctgov"
      },
      {
        "drug_name": "OMEPRAZOLE",
        "type": "phase_advanced",
        "date": "2015-04-01",
        "source": "ctgov"
      },
      {
        "drug_name": "TICAGRELOR",
        "type": "phase_advanced",
        "date": "2015-04-01",
        "source": "ctgov"
      },
      {
        "drug_name": "Celecoxib",
        "type": "phase_advanced",
        "date": "2025-10-10",
        "source": "ctgov"
      }
    ],
    "ulcerative colitis": [
      {
        "drug_name": "Atorvastatin",
        "type": "phase_advanced",
        "date": "2021-09-24",
        "source": "ctgov"
      },
      {
        "drug_name": "pembrolizumab",
        "type": "phase_advanced",
        "date": "2025-11-04",
        "source": "ctgov"
      }
    ],
    "systemic lupus erythematosus": [
      {
        "drug_name": "BORTEZOMIB",
        "type": "phase_advanced",
        "date": "2014-10-01",
        "source": "ctgov"
      },
      {
        "drug_name": "Sulfasalazine",
        "type": "phase_advanced",
        "date": "2024-05-06",
        "source": "ctgov"
      }
    ]
  }
}